Cargando…
Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
BACKGROUND: In China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which has show...
Autores principales: | Zhou, Jian-Guo, Zhou, Nan-Jing, Zhang, Qiong, Feng, Yao-yao, Zhou, Hang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142681/ https://www.ncbi.nlm.nih.gov/pubmed/30223869 http://dx.doi.org/10.1186/s13063-018-2858-2 |
Ejemplares similares
-
Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial
por: Hou, Zhiguo, et al.
Publicado: (2023) -
Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial
por: Pan, Lanlan, et al.
Publicado: (2022) -
Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019) -
Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial
por: Wang, Kang-Xin, et al.
Publicado: (2021) -
Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
por: Wu, Shuo, et al.
Publicado: (2020)